About

About Celluris Celluris is the first Latin American company developing personalized treatment for cancer patients through CAR-T immunotherapy for Solid Tumors. This technique is based on the modification of the patient’s cells into recognizing the tumor as a target, fighting it accurately. Celluris’ novel solution, RfuCAR, was engineering to respond to some challenges in the field. RfuCAR is a bispecific receptor CAR, composed by an antigen binding domain and another domain that binds to an extracellular molecule from tumoral microenvironment. Therefore, RfuCAR can modulate the tumoral microenvironment by trapping an extracellular molecule, reducing inhibitory signaling and improving the CAR anti-tumoral function. In addition, our platform encompasses a switch on/off/modulation system to control toxicity, so with administration of small peptides that will block CAR epitopes, it will be possible to minimize the effects of CRS and neurotoxicity, very common in patients treated with CAR-T therapy. Our first targets will be lung, pancreatic and mesothelioma tumors, we already obtained some encouraging in vitro data, showing almost 30% of tumoral epithelial cells killing. With P&D located in São Paulo, Brazil, and with office in US, Celluris was co-founded by Yechiel Stern and Patricia Rozenchan.